Table 1. Clinical studies to date using MVA-NP+M1 (Total n=151).
| Country | Study | Vaccine | Age | Route | Dose of MVA-
NP+M1 |
Number of
volunteers |
|---|---|---|---|---|---|---|
| UK | FLU001 | MVA-NP+M1 | 18–50 | ID | 5 ×10 7 pfu | 12 |
| MVA-NP+M1 | 18–50 | IM | 5 ×10 7 pfu | 8 | ||
| MVA-NP+M1 | 18–50 | IM | 2.5 ×10 8 pfu | 8 | ||
| MVA-NP+M1 | 50–59 | IM | 1.5 ×10 8 pfu | 10 | ||
| MVA-NP+M1 | 60–69 | IM | 1.5 ×10 8 pfu | 10 | ||
| MVA-NP+M1 | 70+ | IM | 1.5 ×10 8 pfu | 10 | ||
| UK | FLU002 | MVA-NP+M1 | 18–50 | IM | 1.5 ×10 8 pfu | 15 |
| UK | FLU003 | MVA-NP+M1 (together with seasonal influenza
vaccine) |
50+ | IM | 1.5 ×10 8 pfu | 9 |
| UK | FLU004 | ChAdOx1-NP+M1/MVA-NP+M1 ( 7–14 weeks apart) | 18–50 | IM | 1.5 ×10 8 pfu | 3 |
| UK | FLU005 | ChAdOx1-NP+M1 / MVA-NP+M1 (8 weeks apart) | 18–50 | IM | 1.5 ×10 8 pfu | 12 |
| ChAdOx1-NP+M1 / MVA-NP+M1 (52 weeks apart) | 18–50 | IM | 1.5 ×10 8 pfu | 8 | ||
| MVA-NP+M1 / ChAdOx1-NP+M1 (8 weeks apart) | 18–50 | IM | 1.5 ×10 8 pfu | 13 | ||
| ChAdOx1-NP+M1 / MVA-NP+M1 (52 weeks apart) | 18–50 | IM | 1.5 ×10 8 pfu | 12 | ||
| ChAdOx1-NP+M1 / MVA-NP+M1 (8 weeks apart) | >50+ | IM | 1.5 ×10 8 pfu | 12 | ||
| UK | FLU006 | MVA-NP+M1 (
co-administered with seasonal
influenza vaccine - Viroflu® |
>50 | IM | 1.5 ×10 8 pfu | 3 |
| UK | FLU008 | MVA-NP+M1 (AGE1.CR.pIX cell line) | 18–50 | IM | 1.5 ×10 8 pfu | 6 |